DarioHealth Regains Nasdaq Compliance

After nearly a year under pressure, the company’s stock maintained a $1.00 bid price long enough to resolve the issue.

September 15, 2025

Compliance Restored After Twelve-Month Gap

On September 12, DarioHealth confirmed it had met Nasdaq’s minimum bid price requirement, closing out a compliance issue that had been active since last fall. The company received the notice from Nasdaq after maintaining a $1.00 closing bid price for ten straight trading days, from August 28 through September 11.

The original issue surfaced in September 2024, when DarioHealth’s stock dipped below the $1.00 threshold set under Nasdaq Listing Rule 5550(a)(2). That triggered a countdown. Companies that fall out of compliance with this rule are given a defined period to correct the issue or risk being delisted.

DarioHealth met the challenge. By hitting the $1.00 mark consistently over the required period, it regained good standing. Nasdaq has now closed the matter.

Next Steps for DarioHealth

This gives the company room to move forward without the weight of an unresolved listing issue. DarioHealth builds digital health solutions for chronic condition management—areas like diabetes, hypertension, and behavioral health. Regulatory compliance plays a key role in supporting that mission. Staying listed on a national exchange gives the company access to capital and keeps it visible to investors.

The update was signed by CFO Chen Franco-Yehuda. With the compliance issue behind it, the team can now stay focused on execution—bringing new features to market, delivering value to customers, and driving adoption across its platform.